FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
M Milella - New England Journal of Medicine, 2011 - iris.univr.it
M Milella
New England Journal of Medicine, 2011•iris.univr.itConroy et al.(May 12 issue) 1 report that FOLFIRINOX (a combination chemotherapy
regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin) provided a
statistically and clinically significant benefit over single-agent gemcitabine in patients with
advanced pancreatic cancer. Although the increased toxicity associated with this
combination therapy may temper enthusiasm, this is the first real advance in such therapy
since the introduction of gemcitabine.
regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin) provided a
statistically and clinically significant benefit over single-agent gemcitabine in patients with
advanced pancreatic cancer. Although the increased toxicity associated with this
combination therapy may temper enthusiasm, this is the first real advance in such therapy
since the introduction of gemcitabine.
Abstract
Conroy et al.(May 12 issue) 1 report that FOLFIRINOX (a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin) provided a statistically and clinically significant benefit over single-agent gemcitabine in patients with advanced pancreatic cancer. Although the increased toxicity associated with this combination therapy may temper enthusiasm, this is the first real advance in such therapy since the introduction of gemcitabine.
iris.univr.it